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Abstract
Objective: The main objectives of this study were to investigate the prevalence of hepatitis C virus (HCV) 
among patients with β-thalassemia major and to determine the most prevalent genotype for this virus.
Materials and Methods: One hundred twenty-two β-thalassemia major patients who were previously 
diagnosed at the molecular level were included. All plasma samples were tested for the presence of anti-
bodies by ELISA. Real-time polymerase chain reaction (PCR) was used in the quantitation the HCV 
RNA viral loads, and consequently, patients with high virus titer were genotyped by the linear array.
Results: Forty of the patients were anti-HCV positive. The prevalence of anti-HCV was significantly 
higher in patients who received blood transfusion before 1993 (83.7%) than in those who received it after 
1993 (16.3%) (p=0.000). β-thalassemia major patients with HCV infection had significantly higher rates 
of elevated aspartate aminotransferase (54.4% vs 40.5%, p=0.045) and alanine aminotransferase 
(72.47% vs 37.47%, p=0.00) and of splenectomy (54.8% vs 45.2%, p=0.004) than β-thalassemia major 
patients without HCV.
Conclusion: HCV genotype 4 is the commonest genotype in multi-transfused patients with β-thalassemia 
major in Jordan.  (Turk J Hematol 2011; 28: 47-51)
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Özet
Amaç: Bu çalışma kapsamında, β-talasemi majörlü hastalarda HCV prevalansının araştırılması ve bu 
virüsün söz konusu hastalar arasında en yaygın genotipinin belirlenmesi amaçlanmaktadır.
Yöntem ve Gereçler: Önceden moleküler düzeyde tanı konan 122 β-talasemi majörlü hasta çalışmaya 
alınmıştır. Tüm plazma numuneleri antikor varlığına yönelik olarak ELISA ile test edilmiştir. HCV RNA Introduction
Beta-thalassemia is an autosomal recessive dis-
order and occurs because of the absence or reduced 
synthesis of the beta globin chains [1]. Patients with 
beta-thalassemia major (β-TM) suffer from numer-
ous complications such as massive hepatospleno-
megaly, dental problems, leg ulcers, and high risk 
for acquiring blood-transmitted infections such as 
hepatitis B virus (HBV), human immunodeficiency 
virus (HIV) and particularly hepatitis C virus (HCV) 
[2,3]. According to estimates by the World Health 
Organization, 170 million people are infected with 
HCV worldwide [4]. HCV genome encodes a single 
poly protein of 3000 amino acids; it is cleaved post 
translationally to yield at least 10 structural and non-
structural proteins [5]. Sequence comparisons of 
the virus led to the identification of at least six major 
genotypes [6], and these differ in nucleotide 
sequence by more than 30% over the complete 
virus genome. Additionally, there are more than 50 
subtypes, which also differ in nucleotides sequence 
by more than 20% [7]. Genotype 4 is found most 
commonly in the Middle East [8]. Genotyping and 
sub-typing for HCV are not only required for therapy 
initiation and monitoring, but they also assist in vac-
cine development [9,10]. Studies have shown that 
HCV genotypes 1 and 4 are more resistant to treat-
ment with pegylated interferon and ribavirin than 
genotypes 2 and 3 [11]. 
A study conducted in Jordan among patients on 
regular hemodialysis showed that the prevalence of 
HCV infection was correlated with the history of 
blood transfusion before the introduction of anti-
HCV screening in Jordanian blood banks in 1993 
[12]. HCV genotype 1a was found to be the pre-
dominant sub-type among blood donors and 
Jordanian hemodialysis patients as well as other 
Middle Eastern countries including Lebanon, Turkey, 
Cyprus, and Syria [13,14].  HCV genotype 4 is the 
most prevalent in Saudi Arabia, Egypt, Yemen, and 
Bahrain [15].  Patients with hemoglobinopathies 
have been excluded from large studies of therapy 
for HCV, particularly studies that include ribavirin, 
because of the associated blood  hemolysis [16]. 
Both ribavirin and interferon drugs were tested on 
thalassemic patients with HCV infection and were 
shown to be effective [17]. The main objectives of 
this study were (i) to investigate the prevalence of 
HCV among Jordanian patients with β-TM, and (ii) 
to determine the most prevalent genotype for this 
virus.
Materials and Methods
A hospital-based study was carried out on 122 
patients pre-diagnosed with β-TM based on hemo-
globin electrophoresis and molecular DNA analysis 
between April -December 2008. Identification of 
β-TM for over 150 patients, including the patients of 
this study, was achieved by polymerase chain reac-
tion (PCR) amplification of beta-globin genes and 
direct DNA sequencing of amplified genomic DNA. 
All patients receive regular blood transfusions 
every 2-4 weeks in Princess Rahmah Governmental 
Hospital, Irbid, Jordan. All study subjects provided 
written informed consent or consent was obtained 
from their guardian in the case of minors, and the 
study was approved by the Institutional Review 
Board of Jordan University of Science and 
Technology. Blood samples were drawn from 
patients before the scheduled transfusion, and 
viral yükler ve dolayısıyla doğrusal dizilim ile genotiplenen yüksek virüs titreli hastalar gerçek zamanlı 
PCR kullanarak belirlenmiştir. 
Bulgular: Hastaların 40’ı anti-HCV pozitif idi. Anti-HCV prevalansı, 1993’ten önce kan transfüzyonu 
uygulanan hastalarda (%83.7), 1993’ten sonra uygulananlara (%16.3) kıyasla anlamlı derecede daha 
yüksek idi (p=0.00). HCV enfeksiyonlu β-talasemi majörlü hastaların Aspartat aminotransferaz (%54.4; 
%40.5, p= 0.045) ve Alanin aminotransferaz (%72.47; %37.47, p= 0.00) düzeyleri HCV enfeksiyonsuz 
β-talasemi majörlü hastalarınkine kıyasla anlamlı derecede daha yüksek olup, bu gruptaki splenektomize 
hastaların sayısı anlamlı derecede daha yüksek idi (%54.8; %45.2, p= 0.004). 
Sonuç: Ürdün’de, multipl transfüzyon uygulanmış β-TM’li hastalarda genotip 4, en yaygın genotiptir.   
(Turk J Hematol 2011; 28: 47-51)
Anahtar kelimeler: Viroloji, transfüzyon, talasemi
Geliş tarihi: 07 Ağustos 2009     Kabul tarihi: 22 Şubat 2010 
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at -80°C until analysis. All plasma samples were 
tested using the GENEDIA ELISA 3.0 kit (Green Cross 
Medical Science Corp, Korea) for the presence of 
antibodies directed against four HCV genomic 
regions: Core, NS3, NS4, and NS5.
Total RNA was extracted from ELISA-positive 
samples by the Ribo-Virus spin column extraction 
kit (Saccace, Italy) according to the manufacturer’s 
specifications. Quantification of the viral load (HCV-
RNA) in serum was done by amplification method 
using the HCV Real-TM Quant MX kit (Sacace, Italy) 
according to the manufacturer’s specifications. The 
emission of a reporter dye probe specific for HCV, 
which is proportional to the amount of HCV RNA in 
the starting sample, was measured using MX4000TM 
(Stratagene, USA). 
Samples with high viral loads were genotyped 
using the linear array HCV genotyping test kit, ver-
sion 2.0 (Roche Molecular System) according to 
manufacturer’s specifications. Statistical analysis 
was performed using the Statistical Package for 
Social Sciences (SPSS, version 16.0) software. 
Differences between β-TM patients with and with-
out HCV infection were analyzed using the t-test 
and chi-square test where applicable. Statistical 
significance was considered at a p value <0.05.
Results
A total of 122 β-TM patients (67 males, 55 females) 
were studied, and their ages ranged from 2-40 years 
old (mean age: 14.5 years). A total of 12 different 
mutations were detected, with the IVS1-110 (G>A) 
mutation found to be the more frequent among 
Jordanians (manuscript in preparation). Forty 
patients were anti-HCV positive. The prevalence of 
anti-HCV was significantly higher in patients who 
received blood transfusion before 1993 (83.7%) than 
in those who received it after 1993 (16.3%) (p=0.00) 
(Table 1). β-TM patients with HCV infection had a 
significantly higher rate of elevated aspartate amino-
transferase (AST) (54.4% vs 40.5%, p=0.045), ala-
nine aminotransferase (ALT) (72.47% vs 37.47%, 
p=0.00) and of splenectomy (54.8% vs 45.2%, 
p=0.004) than β-TM patients without HCV (Tables 1, 
2). Factors with no statistical significance between 
the two groups were gender, hemoglobin level, fer-
ritin level, drug intake, and alkaline phosphatase 
level (Tables 1, 2). 
Twenty of 40 samples with ELISA-positive test 
had high viral loads using the real time PCR assay. 
HCV genotype 4 was found in 12 patients with high 
viral titer. Two patients refused to participate in 
completing the study and genotyping array failed for 
the other six samples (3 of the failed samples were 
from patients under prolonged treatment with inter-
feron and ribavirin).
Discussion
Several studies have shown that patients with 
β-TM receiving chronic blood transfusions have a 
higher prevalence of chronic HCV infection, particu-
larly if transfused before HCV serological testing 
became available [18]. Patients with hemoglobin-
opathies, mainly with thalassemia, have tradition-
ally been excluded from large studies of therapy of 
HCV [19], particularly studies that include ribavirin 
because of the associated hemolysis leading to an 
increase in transfusion requirement, iron accumula-
tion and the risk of iron-related toxicities [20]. 
A study done among 142 HCV-infected Lebanese 
thalassemic patients identified HCV genotype 4 as 
the predominant genotype among thalassemic 
patients, which is in agreement with our results, 
and this confirms the predominance of HCV geno-
type 4 in our country and perhaps in the Middle East 
[21]. Another study involving 104 thalassemic 
patients in Thailand showed that prevalence of HCV 
infection among Thai thalassemic patients was 
20.2% [2], while a higher prevalence of HCV infec-
tion was observed in our study, with a frequency of 
32.8%. Wanachiwanawin et al. [2] showed that 
patients with anti-HCV antibodies had significantly 
higher levels of serum AST and ALT than patients 
without anti-HCV antibodies (p=0.021 and 0.017, 
respectively), in agreement with our results, which 
revealed that HCV-infected patients had significant-
ly higher levels of ALT and AST than patients with-
out anti-HCV (p=0.045 and 0.000, respectively). 
A study done among 283 Jordanian hemodialysis 
patients showed that 98 (34.6%) patients were anti-
HCV-positive by ELISA, two HCV genotypes (1 and 4) 
were identified and HCV genotype la was predomi-
nant, whereas in our results, only genotype 4 was 
identified, and in six samples the genotype arrays 
failed (3 of the samples were from patients under 
extended treatment with interferon and ribavirin). 
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variant or a mixed infection that can not be detect-
ed using this genotyping kit [22].
In a study done in Iran in 2006 among 732 
patients with β-TM and141 (19.3%) patients who 
were anti-HCV positive showed that older age 
(p=0.001), longer transfusion duration (p=0.000) 
and higher serum ferritin level (p=0.002) were sig-
nificantly associated with a higher prevalence of 
HCV [23]. These results are in agreement with our 
results except for the ferritin level, since we deter-
mined no statistical significance for the association 
between ferritin level and HCV infection. However, 
our study showed that splenectomized β-TM patients 
have a higher prevalence of HCV infection. 
Splenectomized patients are probably heavily trans-
fused with blood before splenectomy due to hyper-
splenism. 
In conclusion, HCV genotype 4 is the common-
est genotype in multi-transfused patients with 
β-TM in Jordan. Considering the possibilities of 
HCV mixed genotype among patients with thalas-
semia, accuracy and precision should be an impor-
tant concern in the detection of genotypes, which 
might explain the genotyping failure in six patients 
with high viral load.
Conflict of interest statement
None of the authors of this paper has a conflict of 
interest, including specific financial interests, rela-
tionships, and/or affiliations relevant to the subject 
matter or materials included.
References
1.  Sadeghi-Bojd S, Hashemi M, Karimi M. Renal tubular 
function in patients with β-thalassaemia major in 
Zahedan, southeast Iran. Singapore Med J 2008;49:410-2.
2.  Wanachiwanawin W, Luengrojanakul P , Sirangkapracha 
P , Leowattana W, Fucharoen S. Prevalence and clinical 
significance of hepatitis C virus infection in Thai patients 
with thalassemia. Int J Hematol 2003;78:374-8. [CrossRef]
3.  Forget BG. Thalassemia syndromes. In: Hoffman R, 
Benz E J, Shathl S J, Furie B, Cohen HJ, Silberstein LE, 
Mcglare P , editors. Hematology Basic Principles and 
Practice. 3rd ed. Philadelphia: Churchill Livingstone, 
2000:485-510.
4.  Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, 
diagnosis and management of antiviral therapy. World 
J Gastroenterol 2007;13:2461-6.
5.  Lauer GM, Walker BD. Hepatitis C virus infection. 
N Engl J Med 2001;345:41-51. [CrossRef]
6.  Simmonds P , Holmes EC, Cha TA, Chan SW, McOmish 
F, Irvine B, Beall E, Yap PL, Kolberg J, Urdea MS. 
Classification of hepatitis C virus into six major geno-
types and a series of subtypes by phylogenetic analysis 
of the NS-5 region. J Gen Virol 1993;74:2391-9. 
[CrossRef]
7.  Simmonds P , Alberti A, Alter HJ, Bonino F, Bradley DW, 
Brechot C, Brouwer JT, Chan S-W, Chayama K. A pro-
posed system for the nomenclature of hepatitis C viral 
genotypes. Hepatol 1994;19:1321-4. [CrossRef]
8.  Dixit V, Quan S, Martin P , Larson D, Brezina M, DiNello 
R, Sra K, Lau JY, Chien D, Kolberg J, et al. Evaluation of 
a novel serotyping system for hepatitis C virus: strong 
correlation with standard genotyping methodologies. 
J Clin Microbiol 1995;33:2978-83.
9.  Stuyver L, Vanarnhem W, Wyseur A, Hernandez F, 
Delaporte E, Maertens G. Classification of hepatitis C 
viruses based on phylogenetic analysis of the envelope 
1 and non-structural 5B regions and identification of 
five additional subtypes. Proc Natl Acad Sci USA 
1994;91:10134-8. [CrossRef]
10.  Maertens G, Stuyver L. Typing of hepatitis C virus iso-
lates. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, 
editors. Viral Hepatitis and Liver Disease. Turin: Minerva 
Medica, 1997:181-6.
11.  Mahaney K, Tedeschi V, Maertens G, Bisceglie A, 
Vergalla J, Hoofnagle J, Sallie R. Genotypic analysis of 
hepatitis C virus in American patients. Hepatology 
1994;20:1405-14. [CrossRef]
12.  Salwa B. Hepatitis C virus infection in Jordanian hae-
modialysis units: serological diagnosis and genotyping. 
J Med Microbiol 2002;51:700-4.
Table 1. Age discrimination and laboratory findings of patients 
  HCV-infected  HCV-not infected  p value
Age (years)  19.08±6.03  12.1±7.5  <0.001 
(Mean±SD)
ALT (U/L)  72.47  37.47  <0.001 
AST (U/L)  54.4  40.50  0.045
ALP (U/L)  209.12  213.04  0.90
Ferritin (mg/dl)  2131.95  2013.68  0.69
Hb (g/dl)  8.76  8.79  0.86
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline 
phosphatase; Hb: Hemoglobin
Table 2. Risk factors for HCV infection other than blood transfusion in 
β-TM patients
Characteristic  HCV-infected   HCV-not   p value
    patients (%)  infected (%)
Surgery   44.7  55.3  0.062
Deferoxamine intake  38.4  61.6  0.58
Splenectomy 54.8  45.2  0.004
Family history of β-TM 37.5  62.5  0.76
Gender  Male  33.3  66.7  0.83
 Female  34.6  65.4 
Al-Sweedan et al.
Genotyping of HCV in β-TM Turk J Hematol 2011; 28: 47-51 5013.  Dusheiko G, Schmilovitz H, Brown D. Hepatitis C virus 
genotypes: an investigation of type-specific differences 
in geographic origin and disease. Hepatol 1994;19:13-8. 
[CrossRef]
14.  Abdulkarim AS, Zein NN, Germer JJ. Hepatitis C virus 
genotypes and hepatitis G virus in hemodialysis 
patients from Syria: identification of two novel hepatitis 
C virus subtypes. Am J Trop Med Hyg 1998;59:571-6.
15.  Davidson F, Simmonds P , Ferguson JC. Survey of major 
genotypes and subtypes of hepatitis C virus using RFLP 
of sequences amplified from the 59 non-coding region. 
J Gen Virol 1995;76:1197-204. [CrossRef]
16.  Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin 
as frontline treatment for chronic hepatitis C infection 
in thalassaemia major. Br J Haematol 2002;117:755-8. 
[CrossRef]
17.  Marco V, Iacono L, Capra M, Grutta S, Ciaccio C, 
Gerardi C, Maggio A, Renda D, Almasio P , Pisa R, Craxi 
A. Alpha interferon treatment of chronic hepatitis C in 
beta-thalassaemia. Gut 1993;34 (2 Suppl):S142-3.
18.  Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. 
Complications of b-thalassemia major in North 
America. Blood 2004;104:34-9. [CrossRef]
19.  Strader DB. Understudied populations with hepatitis C. 
Hepatology 2002;36:226-36. [CrossRef]
20.  Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP , 
Skaug K. Raised serum ferritin predicts nonresponse to 
interferon and ribavirin treatment in patients with 
chronic hepatitis C infection. Liver 2002;22:269-75. 
[CrossRef]
21.  Sharara AI, Ramia S, Ramlawi F, Fares JE, Klayme S, 
Naman R. Genotyping of hepatitis C virus (HCV) 
among positive Lebanese patients: comparison of data 
with that from other Middle Eastern countries. 
Epidemiol Infect 2007;135:427-32. [CrossRef]
22.  Bdour S. Hepatitis C virus infection in Jordanian hae-
modialysis units: serological diagnosis and genotyping. 
J Med Microbiol 2002;51:700-4.
23.  Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, 
Yektaparast B, Zahedi MJ, Zand V, Azami AA, Hosseini 
MM, Faridi AR, Davari K, Hajibeigi B. Epidemiology of 
hepatitis B, hepatitis C, and human immunodeficiency 
virus infections in patients with beta-thalassemia in 
Iran: a multicenter study. Arch Iran Med 2006;9:319-23.
Al-Sweedan et al.
Genotyping of HCV in β-TM Turk J Hematol 2011; 28: 47-51 51